Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

Table 1 Histological and clinical characteristics of colorectal cancer patients, n (%)

Variable	Value
Gender
Male	112 (54.6)
Female	93 (45.4)
Age (yr)
≥ 60	106 (51.7)
< 60	99 (48.3)
Primary site
Colon	140 (68.3)
Rectum	65 (31.7)
Tumor type
Exophytic type	151 (73.7)
Ulcerative type	54 (26.3)
LVI
Present	64 (31.2)
Absent	141 (68.8)
PNI
Present	58 (28.3)
Absent	147 (71.7)
EMVI
Present	31 (15.1)
Absent	174 (84.9)
LNM
Present	89 (43.4)
Absent	116 (56.6)
PDC
Present	152 (74.1)
Absent	53 (25.9)
TB
BD1	117 (57.1)
BD2	40 (19.5)
BD3	48 (23.4)
Histologic differentiation
P/D or mucinous	53 (25.9)
M/D	142 (69.3)
W/D	10 (4.9)
Tumor stage
I	34 (16.6)
II	72 (35.1)
III	80 (39.0)
IV	19 (9.3)
c-MET immunohistochemistry
0	3 (1.4)
1+	51 (24.9)
2+	112 (54.7)
3+	39 (19.0)
MET FISH (Cappuzzo criteria)
MET GCN ≥ 5	28 (14.4)
MET GCN < 5	167 (85.6)
MET FISH (PathVysion criteria)
MET/CEP7 ≥ 2	0 (0.0)
MET/CEP7 < 2	195 (100.0)

EMVI: Extramural venous invasion; GCN: Gene copy number; LNM: Lymph node metastasis; LVI: Lymphovascular invasion; M/D: Moderately differentiated; P/D: Poorly differentiated; PDC: Poorly differentiated clusters; PNI: Perineural invasion; TB: Tumor budding; W/D: Well differentiated.